ALLMedicine™ Acromegaly Center

Apr 21st, 2021 - A giant retrosternal goiter can lead to compression of vital organs in the mediastinum with high risk of acute cardiorespiratory decompensation. Additionally, patients with acromegaly are prone to developing severe airway obstruction and ventilati...

Apr 19th, 2021 - Acromegaly can impair bone integrity, increasing the risk of vertebral fractures (VF). To evaluate the impact of isolated GH/IGF-I hypersecretion on bone turnover markers,Wnt inhibitors, BMD, microarchitecture, bone strength and vertebral fracture...

Apr 17th, 2021 - Soluble alpha klotho (sαKL) has been linked to growth hormone (GH) action, but systematic evaluation and comparison to traditional biomarkers in acromegaly are lacking. To evaluate the potential of sαKL to aid classification of disease activity. R...

Apr 16th, 2021 - Diabetes mellitus (DM) represents one of the most frequent comorbidities in patients with acromegaly. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) represent an important class for diabetes management. However, limited data is reported regard...

Apr 15th, 2021 - Acromegaly is a rare disease caused by high serum levels of growth hormone (GH) and insulin-like growth factor 1 (IGF-1), often originating from a pituitary adenoma. Spinal and peripheral joint abnormalities are caused by these hormonal hypersecre...

Feb 25th, 2016 - Hyperglycemia is a common feature associated with states of increased growth hormone secretion and glucocorticoid levels. The purpose of these guidelines is to assist clinicians and other health care providers to take evidence-based therapeutic de...

Dec 31st, 2015 - Hyperglycemia is a common feature associated with states of increased growth hormone secretion and glucocorticoid levels. The purpose of these guidelines is to assist clinicians and other health care providers to take evidence-based therapeutic de...

Oct 30th, 2014 - The aim was to formulate clinical practice guidelines for acromegaly. The Task Force included a chair selected by the Endocrine Society Clinical Guidelines Subcommittee (CGS), five experts in the field, and a methodologist. The authors received no...

Feb 25th, 2014 - In March 2013, the Acromegaly Consensus Group met to revise and update guidelines for the medical treatment of acromegaly. The meeting comprised experts skilled in the medical management of acromegaly. The group considered treatment goals covering...

Aug 23rd, 2011 - American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly--2011 update.|2011|Katznelson L,Atkinson JL,Cook DM,Ezzat SZ,Hamrahian AH,|diagnosis,therapy,standards,trends,...

Apr 21st, 2021 - A giant retrosternal goiter can lead to compression of vital organs in the mediastinum with high risk of acute cardiorespiratory decompensation. Additionally, patients with acromegaly are prone to developing severe airway obstruction and ventilati...

Apr 19th, 2021 - Acromegaly can impair bone integrity, increasing the risk of vertebral fractures (VF). To evaluate the impact of isolated GH/IGF-I hypersecretion on bone turnover markers,Wnt inhibitors, BMD, microarchitecture, bone strength and vertebral fracture...

Apr 17th, 2021 - Soluble alpha klotho (sαKL) has been linked to growth hormone (GH) action, but systematic evaluation and comparison to traditional biomarkers in acromegaly are lacking. To evaluate the potential of sαKL to aid classification of disease activity. R...

Apr 16th, 2021 - Diabetes mellitus (DM) represents one of the most frequent comorbidities in patients with acromegaly. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) represent an important class for diabetes management. However, limited data is reported regard...

Apr 15th, 2021 - Acromegaly is a rare disease caused by high serum levels of growth hormone (GH) and insulin-like growth factor 1 (IGF-1), often originating from a pituitary adenoma. Spinal and peripheral joint abnormalities are caused by these hormonal hypersecre...

Sep 15th, 2020 - Answer 5/5 Which of the following is accurate regarding treatment of acromegaly? Your peers chose: Pharmacologic therapy is the first-line treatment for acromegaly 0% Radiation therapy is routinely indicated for most patients with acromegaly 0% Fo...

Sep 15th, 2020 - Causes of excess IGF-I action can be divided into the following three categories: Release of primary GH excess from the pituitary Increased GHRH secretion or hypothalamic dysregulation Hypothetically, the excessive production of IGF-binding protei...

Sep 15th, 2020 - Gigantism refers to abnormally high linear growth due to excessive action of insulin-like growth factor I (IGF-I) while the epiphyseal growth plates are open during childhood. Acromegaly is the same disorder of IGF-I excess but occurs after the gr...

Sep 15th, 2020 - Gigantism is extremely rare, with approximately 100 reported cases to date. Acromegaly is more common than gigantism, with an incidence of 3-4 cases per million people per year and a prevalence of 60 cases per million population. A claims-based an...

Jun 28th, 2020 - The US Food and Drug Administration (FDA) has approved oral octreotide (Mycapssa, Chiasma) delayed-release capsules for the long-term maintenance treatment of patients with acromegaly who previously responded to and tolerated octreotide or lanreot...